Because of worsening of ocular and joint symptoms, GLM therapy was added to the existing regimen of weekly subcutaneous methotrexate (25 mg) and once daily topical steroid.
Two out of three patients had control of ocular and joint inflammation on GLM therapy and were able to undergo cataract surgery with continued control of inflammation and improvement in visual acuity.
Given continued active inflammation on oral corticosteroids and methotrexate, GLM therapy was initiated at 50 mg subcutaneously once per month with quiescence of ocular and joint disease within 2 months of starting therapy.
Patient 2 may have had an initial response to GLM but then developed recurrence of both ocular and joint symptoms and has failed numerous other therapies, which indicates that GLM may not be superior to other TNF inhibitors for patients with severe disease.
The patient responded well to monthly infusions of infliximab with resolution of ocular and joint-related symptoms.
The dengue cases were mainly diagnosed based on dengue fever symptoms, including fever, headache, retro-ocular and joint pain, rash, lymphadenopathy, and positive DENV nonstructural protein (NS) 1 antigen detected with the Dengue Ag Rapid Test (CTK Biotech, Inc., San Diego, CA), which is the standard method used to rapidly detect antigens in DENV infections.
To investigate ocular anomalies in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type (JHS/EDS-HT).
Our research protocol included the evaluation of sensitive factors capable of affecting the posture, such and podal factor, temporal mandibular joint, ocular and vestibular system.
Two months later, the patient presented with uncontrolled ocular inflammation and joint pain, for which three infusions of 50 100 mg intravenous methotrexate combined with 1 g of intravenous methyl prednisolone were administered while obtaining insurance approval for infliximab therapy.
Indwelling medical devices such as catheters, heart valves, vascular bypass grafts, ocular lenses, artificial joints, cardiac stents, and central nervous shunts have become an integral and indispensable part of modern day clinical practice.
